Life sciences company Revvity (NYSE:RVTY) announced in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0 ...

Revvity (NYSE:RVTY) has had a great run on the share market with its stock up by a significant 10% over the last three months. But the company's key financial indicators appear to be differing across ...

Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...

Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development of novel gene editing therapies This new Pin-point ...

Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday. The company posted quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $1.13 per share ...

In the last three months, 8 analysts have published ratings on Revvity (NYSE:RVTY), offering a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Revvity, Inc. RVTY recently introduced Signals Xynthetica, a next-generation AI-augmented design platform aimed at transforming molecular and materials discovery across scientific industries.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 44 th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and Chief ...